Mellissa Visit 1: Patient-centric Approaches to Dyslipidemia: Risk Recognition and Management of Low HDL-C

Curriculum:
N/A
Credits:
0.5 ACPE 0.5 ANCC Contract Hours 0.5 CDR 0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
08-Mar-11
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

James A. Underberg, MD, MS, FACPM, FACP, FNLA

James Underberg, MD, MS, FACPM, FACP, FNLA
Clinical Assistant Professor of Medicine 
NYU Medical School 
Director, Primary Care Lipid Management Clinic
Bellevue Hospital Lipid Clinic
New York, New York

Dr. Underberg is a Clinical Assistant Professor of Medicine in the Division of General Internal Medicine at NYU Medical School and Director, Primary Care Lipid Management Clinic, Bellevue Hospital. He is also a member of the executive committee of the Division of General Internal Medicine. His clinical focus is Preventive Cardiovascular Medicine. He is an American Society of Hypertension Certified Specialist in Clinical Hypertension, a fellow of the American College of Preventive Medicine, a fellow of the Society for Vascular Medicine & Biology, a Diplomate of the American Board of Clinical Lipidology, and a North American Menopause Society Certified Menopause Practitioner.
 
Dr. Underberg is the founder and President of the New York Preventive Cardiovascular Society and a member of the Board of Directors of the Northeast Chapter of the National Lipid Association. In addition, he is on the editorial board of the Journal of Clinical Lipidology.
 
He graduated from Yale University with a BS and MS and from the University of Pennsylvania Medical School. His internship and residency were completed at Bellevue Hospital Medical Center. He is currently involved in several clinical trials in the areas of hypertension, lipids, diabetes and cardiovascular disease. Dr. Underberg's Clinical Practice was recently awarded recognition by the American Heart Association/American Stroke Association and the National Committee for Quality Assurance Heart-Stroke Recognition Program and the American Diabetes Association Diabetes Prevention Program. He sees patients both in his private referral practice and in the Bellevue Hospital Lipid Clinic.

Danielle Duffy, MD

Danielle Duffy, MD
Assistant Professor of Medicine
Division of Cardiology
Jefferson Medical College and Thomas Jefferson University
Philadelphia, PA

Dr. Duffy is an Assistant Professor of Medicine in the Division of Cardiology at the Jefferson Medical College of Thomas Jefferson University.  She is a clinical cardiologist with a focus on complex lipid management and women's cardiovascular health and prevention.  Dr. Duffy graduated from the University of Pennsylvania School of Medicine and completed her internship and residency at the Hospital of the University of Pennsylvania.  She did additional training in clinical lipidology and lipid research through an NIH sponsored training grant with Dr. Daniel Rader at the University of Pennsylvania prior to completing her fellowship in cardiovascular diseases at Thomas Jefferson University Hospital. Dr. Duffy is the co-PI of several investigator-initiated and site-based research protocols in the area of cardiovascular prevention.

Jan L. McAlister, MSN, APRN, FPCNA, CLS, AACC

Jan L. McAlister, MSN, APRN, FPCNA, CLS, AACC
Adult Nurse Practitioner
Piedmont Heart Institute
Atlanta, GA

Jan McAlister is an Adult Nurse Practitioner at Cardiology of Georgia, PC and the Piedmont Heart Institute. She manages acute clinical cardiology problems which include but are not limited to atrial fibrillation, atherosclerosis, lipids, hypertension, etc.  She was also responsible for establishing the Coumadin Center and Lipid Clinic. She has more than a decade of experience in nursing and cardiology.
1. Discuss the strategy of HDL-C raising and aggressive LDL-C lowering as effective targets of treatment in light of recent clinical trial results.
2. Highlight current concepts in how to diagnose and how and when, and in whom, to treat pathologic states of HDL in clinical patients.
3. Discuss all of the current therapeutic approaches to therapeutically raising HDL levels, emphasizing those that will be available to clinicians first.